All PlansCoverageLow impact
Homocysteine Testing in the Screening, Diagnosis, and Management of Cardiovascular Disease and Venous Thromboembolic Disease
Blue Cross & Blue Shield of Mississippi·MS · Cardiology, Hematology, Family Medicine +2 more·Medical Policy
We identified it
Jun 20, 2026
Summary
This policy confirms that homocysteine testing (CPT 83090) for cardiovascular disease screening and venous thromboembolism risk assessment is considered investigational and therefore not covered. No changes were made in this review - the policy remains unchanged from the previous version.
Action Required
No immediate action required. Billing team should continue current practice of informing patients that homocysteine testing (CPT 83090) for cardiovascular screening or VTE risk assessment is considered investigational and may not be covered by insurance. Consider obtaining advance beneficiary notices (ABNs) for Medicare patients if ordering this test.